United States - English - NLM (National Library of Medicine)

piramal critical care inc - succinylcholine chloride (unii: i9l0ddd30i) (succinylcholine - unii:j2r869a8yf) - succinylcholine chloride injection is indicated in adults and pediatric patients: • as an adjunct to general anesthesia • to facilitate tracheal intubation • to provide skeletal muscle relaxation during surgery or mechanical ventilation. succinylcholine chloride injection is contraindicated: • in patients with skeletal muscle myopathies [see warnings and precautions ( 5.1)] • in patients with known hypersensitivity to succinylcholine. severe anaphylactic reactions to succinylcholine have been reported [see warnings and precautions ( 5.2)] • after the acute phase of injury following major burns, multiple trauma, extensive denervation of skeletal muscle, or upper motor neuron injury, which may result in severe hyperkalemia and cardiac arrest [see warnings and precautions ( 5.4)] • in patients with known or suspected genetic susceptibility to malignant hyperthermia [see warnings and precautions ( 5.5), clinical pharmacology ( 12.5)] risk summary available data from published literature from case reports and case series over decades of use with succinylcholine during pregnancy have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. succinylcholine is used commonly during delivery by caesarean section to provide muscle relaxation. if succinylcholine is used during labor and delivery, there is a risk for prolonged apnea in some pregnant women (see clinical considerations). animal reproduction studies have not been conducted with succinylcholine chloride. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations maternal adverse reactions plasma cholinesterase levels are decreased by approximately 24% during pregnancy and for several days postpartum which can prolong the effect of succinylcholine. therefore, some pregnant patients may experience prolonged apnea. fetal/neonatal adverse reactions apnea and flaccidity may occur in the newborn after repeated high doses to, or in the presence of atypical plasma cholinesterase in, the mother. labor or delivery succinylcholine is commonly used to provide muscle relaxation during delivery by caesarean section. succinylcholine is known to cross the placental barrier in an amount that is dependent on the concentration gradient between the maternal and fetal circulation. risk summary there are no data on the presence of succinylcholine or its metabolite in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for succinylcholine chloride and any potential adverse effects on the breastfed infant from succinylcholine chloride or from the underlying maternal condition. safety and effectiveness of succinylcholine chloride have been established in pediatric patient age groups, neonate to adolescent. because of a risk of ventricular dysrhythmias, cardiac arrest, and death from hyperkalemic rhabdomyolysis in pediatric patients, reserve the use of succinylcholine chloride in pediatric patients for emergency intubation or instances where immediate securing of the airway is necessary, e.g., laryngospasm, difficult airway, full stomach, or for intramuscular use when a suitable vein is inaccessible [see warnings and precautions ( 5.1)] . intravenous bolus administration of succinylcholine chloride in pediatric patients (including infants) may result in profound bradycardia or, rarely, asystole. the incidence and severity of bradycardia is higher in pediatric patients than adults [see warnings and precautions ( 5.6)] . the effective dose of succinylcholine chloride in pediatric patients may be higher than that predicted by body weight dosing alone [see dosage and administration ( 2.3)] . clinical studies of succinylcholine chloride did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

piramal pharma limited - halothane - liquid for inhalation - 100%

United States - English - NLM (National Library of Medicine)

piramal critical care inc - sulbactam sodium (unii: dkq4t82ye6) (sulbactam - unii:s4tf6i2330), ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd) - ampicillin and sulbactam for injection, usp is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. skin and skin structure infections caused by beta-lactamase producing strains of staphylococcus aureus , escherichia coli ,* klebsiella spp.* (including k. pneumoniae* ), proteus mirabilis ,* bacteroides fragilis ,* enterobacter spp.,* and acinetobacter calcoaceticus.* note: for information on use in pediatric patients (see precautions-pediatric use and clinical studies sections). intra-abdominal infections caused by beta-lactamase producing strains of escherichia coli , klebsiella spp. (including k. pneumoniae* ), bacteroides spp. (including b. fragilis ), and enterobacte

United States - English - NLM (National Library of Medicine)

piramal critical care inc - sulbactam sodium (unii: dkq4t82ye6) (sulbactam - unii:s4tf6i2330), ampicillin sodium (unii: jfn36l5s8k) (ampicillin - unii:7c782967rd) - ampicillin and sulbactam for injection, usp is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. skin and skin structure infections caused by beta-lactamase producing strains of staphylococcus aureus , escherichia coli *, klebsiella spp.* (including k. pneumoniae* ), proteus mirabilis *, bacteroides fragilis *, enterobacter spp.*, and acinetobacter calcoaceticus*. note: for information on use in pediatric patients see precautions–pediatric use and clinical studies sections. intra-abdominal infections caused by beta-lactamase producing strains of escherichia coli , klebsiella spp. (including k. pneumoniae* ), bacteroides spp. (including b. fragilis ), and enterobacter

United States - English - NLM (National Library of Medicine)

piramal critical care inc - doxycycline hyclate (unii: 19xts3t51u) (doxycycline anhydrous - unii:334895s862) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline for injection, usp and other antibacterial drugs, doxycycline for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. doxycycline for injection, usp is indicated in infections caused by the following microorganisms: • rickettsiae (rocky mountain spotted fever, typhus fever, and the typhus group, q fever, rickettsial pox and tick fevers) • mycoplasma pneumoniae (pplo, eaton agent). • agents of psittacosis and ornithosis. • agents of lymphogranuloma venereum and granuloma inguinale. • the spirochetal agent of relapsing fever (borrelia recurrentis) . the following g

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

piramal critical care inc - sevoflurane 100% - veterinary inhalation anaesthetics - sevoflurane 100% anaesthetic active 100.0 % - anaesthetics/analgesics - dog | bitch | castrate | puppy - inhalation anaesthetic

Zimbabwe - English - Medicines Control Authority

piramal critical care, inc - sevoflurane - inhalation - 100 %

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

piramal critical care, inc. - isoflurano - isoflurano....100%

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

piramal critical care, inc. - sevoflurano - sevoflurano....1.00 ml

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

piramal pharma limited, india - halothane - liquid - 100